MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317332 | Name: Brimonidine Tartrate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Brimonidine tartrate is a selective AR, α 2 receptor, agonist used to treat glaucoma. Upon ocular administration, brimonidine tartrate acts on the blood vessels causing them to constrict which leads to a decrease in the production of aqueous humor. Brimonidine tartrate enhances the outflow of aqueous humor. This drug is used to reduce intraocular pressure.

Chemical Structure

Brimonidine Tartrate
Brimonidine Tartrate
CAS#70359-46-5 (tartrate)

Theoretical Analysis

MedKoo Cat#: 317332

Name: Brimonidine Tartrate

CAS#: 70359-46-5 (tartrate)

Chemical Formula: C15H16BrN5O6

Exact Mass: 0.0000

Molecular Weight: 442.22

Elemental Analysis: C, 40.74; H, 3.65; Br, 18.07; N, 15.84; O, 21.71

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 Weeks
5g USD 650.00 2 Weeks
10g USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
59803-98-4 (free base) 70359-46-5 (tartrate)
Synonym
Brimonidine Tartrate; AGN 190342; AGN-190342; AGN190342; Alphagan; UK 14,304-18; UK 14,304; UK 14304; UK-14,304-18; UK-14,308
IUPAC/Chemical Name
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;(2R,3R)-2,3-dihydroxybutanedioic acid
InChi Key
QZHBYNSSDLTCRG-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H10BrN5.C4H6O6/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8;5-1(3(7)8)2(6)4(9)10/h1-4H,5-6H2,(H2,15,16,17);1-2,5-6H,(H,7,8)(H,9,10)
SMILES Code
C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.C(C(C(=O)O)O)(C(=O)O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 442.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jackson JM, Knuckles M, Minni JP, Johnson SM, Belasco KT. The role of brimonidine tartrate gel in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2015 Oct 23;8:529-38. doi: 10.2147/CCID.S58920. eCollection 2015. Review. PubMed PMID: 26566370; PubMed Central PMCID: PMC4627400. 2: Erratum: The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]. Clin Ophthalmol. 2015 Jul 22;9:1365. doi: 10.2147/OPTH.S91388. eCollection 2015. PubMed PMID: 26229429; PubMed Central PMCID: PMC4516178. 3: Johnson AW, Johnson SM. The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea. Dermatol Ther (Heidelb). 2015 Sep;5(3):171-81. doi: 10.1007/s13555-015-0078-1. Epub 2015 Jun 26. PubMed PMID: 26112098; PubMed Central PMCID: PMC4580655. 4: Takamura Y, Tomomatsu T, Matsumura T, Takihara Y, Kozai S, Arimura S, Yokota S, Inatani M. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans. J Ocul Pharmacol Ther. 2015 Jun;31(5):282-5. doi: 10.1089/jop.2015.0003. Epub 2015 Apr 28. PubMed PMID: 25918904. 5: Erratum: The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]. Clin Ophthalmol. 2015 Mar 9;9:453. doi: 10.2147/OPTH.S81448. eCollection 2015. PubMed PMID: 25834381; PubMed Central PMCID: PMC4358649. 6: Del Rosso JQ. Reply to "Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea". J Am Acad Dermatol. 2014 Oct;71(4):833-4. doi: 10.1016/j.jaad.2014.06.040. PubMed PMID: 25219709. 7: Swanson LA, Warshaw EM. Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea. J Am Acad Dermatol. 2014 Oct;71(4):832-3. doi: 10.1016/j.jaad.2014.05.073. PubMed PMID: 25219708. 8: Tsumura T, Yoshikawa K, Kimura T, Suzumura H, Kawashima M, Nanno M, Ishijima K, Takeda R. The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients. Clin Ophthalmol. 2014 Sep 1;8:1681-7. doi: 10.2147/OPTH.S67366. eCollection 2014. Erratum in: Clin Ophthalmol. 2015;9:453. Clin Ophthalmol. 2015;9:1365. PubMed PMID: 25214761; PubMed Central PMCID: PMC4159391. 9: Dubey A, Prabhu P. Formulation and evaluation of stimuli-sensitive hydrogels of timolol maleate and brimonidine tartrate for the treatment of glaucoma. Int J Pharm Investig. 2014 Jul;4(3):112-8. doi: 10.4103/2230-973X.138340. PubMed PMID: 25126524; PubMed Central PMCID: PMC4131382. 10: Tong LX, Moore AY. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. Expert Rev Clin Pharmacol. 2014 Sep;7(5):567-77. doi: 10.1586/17512433.2014.945910. Epub 2014 Aug 4. Review. PubMed PMID: 25091290. 11: Fowler J, Tan J, Jackson JM, Meadows K, Jones T, Jarratt M, Leoni M; Brimonidine Phase III Study Group. Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):474-81. doi: 10.1111/jdv.12587. Epub 2014 Jul 30. PubMed PMID: 25074756. 12: Ibrahim F, El-Enany N, El-Shaheny RN, Mikhail IE. Validated spectrofluorimetric and spectrophotometric methods for the determination of brimonidine tartrate in ophthalmic solutions via derivatization with NBD-Cl. Application to stability study. Luminescence. 2015 May;30(3):309-17. doi: 10.1002/bio.2730. Epub 2014 Jul 10. PubMed PMID: 25044105. 13: Fedorchak MV, Conner IP, Medina CA, Wingard JB, Schuman JS, Little SR. 28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres. Exp Eye Res. 2014 Aug;125:210-6. doi: 10.1016/j.exer.2014.06.013. Epub 2014 Jun 28. PubMed PMID: 24983144. 14: Jackson JM, Fowler J, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M; Brimonidine Phase III Study Group. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. J Drugs Dermatol. 2014 Jun;13(6):699-704. PubMed PMID: 24918560. 15: Abramovits W, Prato A, Vincent KD, Scheinfeld N, Gupta AK. MIRVASO (brimonidine tartrate) topical gel 0.33%. Skinmed. 2014 Jan-Feb;12(1):41-3. PubMed PMID: 24720083. 16: Sunitha G, Bhagirath R, Alapati VR, Ramakrishna K, Subrahmanyam CV, Anumolu PD. Fluorimetric quantification of brimonidine tartrate in eye drops. Indian J Pharm Sci. 2013 Nov;75(6):730-2. PubMed PMID: 24591750; PubMed Central PMCID: PMC3928739. 17: Benkali K, Leoni M, Rony F, Bouer R, Fernando A, Graeber M, Wagner N. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea. Br J Dermatol. 2014 Jul;171(1):162-9. doi: 10.1111/bjd.12881. Epub 2014 Jul 16. PubMed PMID: 24506775. 18: Routt ET, Levitt JO. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. J Am Acad Dermatol. 2014 Feb;70(2):e37-8. doi: 10.1016/j.jaad.2013.10.054. PubMed PMID: 24438976. 19: Moore A, Kempers S, Murakawa G, Weiss J, Tauscher A, Swinyer L, Liu H, Leoni M. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014 Jan;13(1):56-61. PubMed PMID: 24385120. 20: Ravindran VK, Repala S, Subadhra S, Appapurapu AK. Chick chorioallantoic membrane model for in ovo evaluation of timolol maleate-brimonidine tartrate ocular inserts. Drug Deliv. 2014 Jun;21(4):307-14. doi: 10.3109/10717544.2013.845272. Epub 2013 Oct 17. PubMed PMID: 24134746.